Roche reports cancer data: Roche Holding stock gains 1.66 percent

Published on 10/07/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales rose 6.00 percent to CHF 30.40 billion in the first half. Roche Holding stock costs EUR 378.35 on October 7, 2026 after EUR 372.18.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH1499059983) was trading at EUR 378.35 at Lang & Schwarz on October 7, 2026 at 10:14 a.m. CEST, up 1.66 percent versus the prior close of EUR 372.18. The latest company catalyst is Roche's October 1, 2026 release on giredestrant combination data in advanced breast cancer, published on the Roche media page.

Breast-cancer data expand the pipeline

The release said the phase III evERA study showed a significant progression-free-survival improvement for the giredestrant combination in ER-positive advanced breast cancer. That result adds a dated oncology catalyst to Roche's development pipeline, although the release describes clinical progress rather than a commercial approval.

Roche also received U.S. FDA filing acceptance under priority review for fenebrutinib on September 30, 2026. According to StockTitan, the Phase III program reduced annualized relapse rates by 51.10 percent and 58.50 percent against teriflunomide in two trials, while the progressive multiple sclerosis study showed a 12.00 percent numerical reduction in progression risk against Ocrevus.

First-half sales rose 6.00 percent

Roche reported first-half 2026 group revenue of CHF 30.40 billion, up 6.00 percent at constant exchange rates, according to Note on figures announced July 23, 2026. Core operating profit reached CHF 11.90 billion, an increase of 10.00 percent at constant exchange rates, and the core operating margin was 39.00 percent.

The combination of revenue growth and a higher core operating profit growth rate puts operating efficiency alongside the pipeline as the key investor variable. Roche's investor calendar lists third-quarter 2026 sales for October 22, 2026 at 2:00 p.m. CEST on its investor page.

Bernstein keeps a CHF 434.50 target

Bernstein Research maintained an Outperform rating and a CHF 434.50 price target on October 6, 2026, according to finanzen.ch. Analyst Justin Smith identified Alzheimer's medicines and Roche's blood-test opportunity as long-term growth areas, giving the pipeline data a valuation context without changing the currency basis of the Lang & Schwarz quote.

Roche Holding stock gains in trading

Roche Holding stock was trading at EUR 378.35 at Lang & Schwarz on October 7, 2026 at 10:14 a.m. CEST, plus 1.66 percent against the prior close of EUR 372.18. The primary listing is on SIX in Swiss francs, while the German investor reference price is the euro quote above. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.